Revelation Biosciences (FRA:56U0) EPS (Basic) : €-28.63 (TTM As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Revelation Biosciences EPS (Basic)?

Revelation Biosciences's basic earnings per share (Basic EPS) for the three months ended in Mar. 2024 was €-2.26. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2024 was €-28.63.

Revelation Biosciences's EPS (Diluted) for the three months ended in Mar. 2024 was €-2.26. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was €-28.63.

Revelation Biosciences's EPS without NRI for the three months ended in Mar. 2024 was €-2.32. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2024 was -31.35.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Revelation Biosciences EPS (Basic) Historical Data

The historical data trend for Revelation Biosciences's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revelation Biosciences EPS (Basic) Chart

Revelation Biosciences Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

EPS (Basic)

-860.58

-140.85

-0.49

Revelation Biosciences Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EPS (Basic)	Get a 7-Day Free Trial								42.52	-6.92	-11.81	-7.64	-2.26

Revelation Biosciences EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Revelation Biosciences's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-0.11	-	0)	/	0.229
	=	-0.48

Revelation Biosciences's Basic EPS for the quarter that ended in Mar. 2024 is calculated as

Basic EPS (Q: Mar. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-2.467	-	0)	/	1.090
	=	-2.26

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-28.63

Revelation Biosciences (FRA:56U0) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Revelation Biosciences EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Revelation Biosciences's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Revelation Biosciences (FRA:56U0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Revelation Biosciences Inc (FRA:56U0) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

REVB:USA 56U1:Germany

Address

4660 La Jolla Village Drive, Suite 100, San Diego, CA, USA, 92122

Website

https://www.revbiosciences.com

Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. It has several product candidates in development. REVTx-99, the lead therapeutic candidate, is an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses such as SARS-CoV-2, including its variants, influenza A and B, parainfluenza, rhinovirus, and RSV. REVTx-99 is also being developed for other indications such as: allergic rhinitis and chronic nasal congestion. REVTx-200 is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx-200 is based on the same technology used in REVTx-99.

Revelation Biosciences (FRA:56U0) Headlines

No Headlines